Hong Kong, May 27 – At the Fattalab new product launch event, representatives from both parties signed a cooperation agreement to jointly build an “Innovative Application Scenario Incubation Platform,” with a focus on promoting the clinical application of the dual-mode liver fibrosis assessment solution—the combined Fibro-Chi × LiverScan detection system.
Fibro-Chi: An innovative rapid detection reagent for liver fibrosis protein marker (CHI3L1) developed by AUISET, specializing in early screening and risk assessment of liver fibrosis.
LiverScan: Utilizes ultrasound to measure liver tissue stiffness values by Eieling, enabling precise assessment of liver hardness to assist in the diagnosis of liver fibrosis and cirrhosis, with a focus on diagnosing later-stage liver diseases.
This signing marks a significant step forward in the field of early liver disease screening. We will continue to deepen our collaboration and jointly advance the “early diagnosis, early treatment” concept for liver fibrosis, contributing to the improvement of liver health in Hong Kong!
